SG159547A1 - Methods and compositions for modulating hyperstabilized c-met - Google Patents

Methods and compositions for modulating hyperstabilized c-met

Info

Publication number
SG159547A1
SG159547A1 SG201000940-5A SG2010009405A SG159547A1 SG 159547 A1 SG159547 A1 SG 159547A1 SG 2010009405 A SG2010009405 A SG 2010009405A SG 159547 A1 SG159547 A1 SG 159547A1
Authority
SG
Singapore
Prior art keywords
met
hyperstabilized
modulating
compositions
methods
Prior art date
Application number
SG201000940-5A
Other languages
English (en)
Inventor
Monica Kong-Beltran
Dineli M Wickramasinghe
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37053941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG159547(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of SG159547A1 publication Critical patent/SG159547A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG201000940-5A 2005-03-25 2006-03-24 Methods and compositions for modulating hyperstabilized c-met SG159547A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66548205P 2005-03-25 2005-03-25

Publications (1)

Publication Number Publication Date
SG159547A1 true SG159547A1 (en) 2010-03-30

Family

ID=37053941

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201000940-5A SG159547A1 (en) 2005-03-25 2006-03-24 Methods and compositions for modulating hyperstabilized c-met

Country Status (18)

Country Link
US (2) US7615529B2 (xx)
EP (1) EP1868648B1 (xx)
JP (2) JP2008535821A (xx)
KR (1) KR20080000613A (xx)
CN (1) CN101184506B (xx)
AU (1) AU2006229989B2 (xx)
BR (1) BRPI0611468A2 (xx)
CA (1) CA2599988A1 (xx)
ES (1) ES2539790T3 (xx)
HK (1) HK1109075A1 (xx)
IL (1) IL185708A (xx)
MX (1) MX2007011652A (xx)
NO (1) NO20075412L (xx)
NZ (1) NZ561211A (xx)
RU (1) RU2404193C2 (xx)
SG (1) SG159547A1 (xx)
WO (1) WO2006104911A2 (xx)
ZA (1) ZA200707953B (xx)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080000613A (ko) * 2005-03-25 2008-01-02 제넨테크, 인크. 과안정화된 ｃ-ｍｅｔ의 조절을 위한 방법 및 조성물
AR070861A1 (es) * 2008-03-06 2010-05-12 Genentech Inc Uso de terapia de combinacion con antagonistas de c-met y egfr
EP2370467B1 (en) * 2008-10-01 2016-09-07 Amgen Research (Munich) GmbH Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
EP2417159A1 (en) 2009-04-07 2012-02-15 Roche Glycart AG Bispecific anti-erbb-3/anti-c-met antibodies
CN102361883A (zh) * 2009-04-07 2012-02-22 罗氏格黎卡特股份公司 双特异性抗-ErbB-1/抗-c-Met抗体
CN106188295A (zh) 2009-04-20 2016-12-07 牛津生物疗法有限公司 特异于钙粘素‑17的抗体
KR101671378B1 (ko) * 2009-10-30 2016-11-01 삼성전자 주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
BR112012010153B1 (pt) * 2009-11-05 2022-05-03 Genentech, Inc Método de produção de um anticorpo
WO2011110642A2 (en) 2010-03-10 2011-09-15 Genmab A/S Monoclonal antibodies against c-met
WO2012054084A2 (en) * 2010-10-20 2012-04-26 Oxford Biotherapeutics Ltd. Antibodies
US20130004484A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
MX2014002289A (es) 2011-08-26 2015-03-20 Merrimack Pharmaceuticals Inc Anticuerpos fc especificos en tandem.
US9201074B2 (en) 2011-09-20 2015-12-01 Eli Lilly And Company Anti-c-Met antibodies
WO2013049112A1 (en) * 2011-09-27 2013-04-04 Emory University Detection of biomarkers using magnetic resonance
KR20130036993A (ko) 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
JP2014533700A (ja) * 2011-11-21 2014-12-15 ジェネンテック， インコーポレイテッド 抗ｃ−ＭＥＴ抗体の精製
US9931400B2 (en) 2012-09-12 2018-04-03 Samsung Electronics Co., Ltd. Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases
PL2766048T3 (pl) 2012-10-12 2015-05-29 Medimmune Ltd Pirolobenzodiazepiny i ich koniugaty
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
US20150259430A1 (en) 2012-11-05 2015-09-17 Mab Discovery Gmbh Method for the production of multispecific antibodies
AU2014225661A1 (en) 2013-03-06 2015-09-10 Merrimack Pharmaceuticals, Inc. Anti-c-Met tandem Fc bispecific antibodies
US20160031887A1 (en) 2013-03-13 2016-02-04 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
US9567641B2 (en) * 2013-07-03 2017-02-14 Samsung Electronics Co., Ltd. Combination therapy for the treatment of cancer using an anti-C-met antibody
CA2941687A1 (en) 2014-03-14 2015-09-17 Genentech, Inc. Methods and compositions for secretion of heterologous polypeptides
RU2016141385A (ru) 2014-03-24 2018-04-28 Дженентек, Инк. Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
BR112017005202A2 (pt) 2014-09-16 2017-12-12 Symphogen As anticorpos anti-met e composições
GB201419108D0 (en) * 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
US20180057595A1 (en) 2015-03-16 2018-03-01 Celldex Therapeutics, Inc. Anti-MET Antibodies and Methods of Use Thereof
EP3778643A1 (en) 2016-09-14 2021-02-17 AbbVie Biotherapeutics Inc. Pharmaceutical uses of anti-pd-1(cd279) antibodies
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
CN113286616A (zh) 2018-05-23 2021-08-20 Adc治疗有限公司 分子佐剂
KR20210044207A (ko) 2018-07-15 2021-04-22 이노치안 바이오파마, 인코포레이티드 암 치료를 위한 재조합 수지상 세포를 사용하는 방법 및 조성물
KR20210132117A (ko) 2019-02-26 2021-11-03 얀센 바이오테크 인코포레이티드 이중특이성 항-EGFR/c-Met 항체를 사용한 병용 요법 및 환자 계층화
WO2020230091A1 (en) 2019-05-14 2020-11-19 Janssen Biotech, Inc. Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
CN114340684A (zh) 2019-09-16 2022-04-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
CN114478788A (zh) 2020-11-11 2022-05-13 高新 一种同时靶向cd3和cd137的融合蛋白及其制备方法和用途
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
EP2014772A3 (en) 1996-04-05 2009-05-27 Antonio Giordano Method for the diagnosis and prognosis of cancer
DK0922102T3 (da) 1996-07-03 2010-08-16 Genentech Inc Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf
CA2481507A1 (en) 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
BRPI0407446A (pt) * 2003-02-13 2006-01-31 Pharmacia Corp Anticorpos para c-met para o tratamento de cânceres
KR101148657B1 (ko) * 2003-06-06 2012-07-05 제넨테크, 인크. Ｈｇｆ 베타 쇄와 ｃ-ｍｅｔ 사이의 상호작용의 변조
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
EP2336178A1 (en) * 2003-12-11 2011-06-22 Genentech, Inc. Methods and compositions for inhibiting C-Met dimerization and activation
PL1718677T3 (pl) 2003-12-19 2012-09-28 Genentech Inc Jednowartościowe fragmenty przeciwciała stosowane jako środki lecznicze
RU2007139516A (ru) 2005-03-25 2009-04-27 Дженентек, Инк. (Us) Мутации с-мет при раке легких
KR20080000613A (ko) 2005-03-25 2008-01-02 제넨테크, 인크. 과안정화된 ｃ-ｍｅｔ의 조절을 위한 방법 및 조성물

Also Published As

Publication number Publication date
CA2599988A1 (en) 2006-10-05
NO20075412L (no) 2007-12-21
CN101184506B (zh) 2013-07-17
BRPI0611468A2 (pt) 2010-09-08
CN101184506A (zh) 2008-05-21
IL185708A (en) 2014-11-30
AU2006229989A1 (en) 2006-10-05
RU2007139452A (ru) 2009-04-27
US20100028337A1 (en) 2010-02-04
IL185708A0 (en) 2008-01-06
HK1109075A1 (en) 2008-05-30
ZA200707953B (en) 2009-06-24
NZ561211A (en) 2011-03-31
ES2539790T3 (es) 2015-07-06
MX2007011652A (es) 2007-11-14
EP1868648B1 (en) 2015-04-15
US8536118B2 (en) 2013-09-17
WO2006104911A2 (en) 2006-10-05
RU2404193C2 (ru) 2010-11-20
KR20080000613A (ko) 2008-01-02
AU2006229989B2 (en) 2012-02-02
US20060270594A1 (en) 2006-11-30
WO2006104911A3 (en) 2007-02-22
JP2012232979A (ja) 2012-11-29
JP2008535821A (ja) 2008-09-04
EP1868648A2 (en) 2007-12-26
US7615529B2 (en) 2009-11-10

Similar Documents

Publication Publication Date Title
SG159547A1 (en) Methods and compositions for modulating hyperstabilized c-met
WO2008033408A3 (en) Methods for identifying compounds that modulate cell signaling and methods employing such compounds
HK1173169A1 (en) Dimercaptan terminated polythioether polymers and methods for making and using the same
CA111398S (en) Bottle
CA111399S (en) Bottle
DE502005005275D1 (de) Verbesserte kakaohaltige mischungen
WO2005107461A3 (en) Modulating lymphatic function
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
HK1092872A1 (en) Modulating the interaction between hgf beta chain and c-met
MX2009006651A (es) Antagonistas de activina-actrii y usos para incrementar los niveles de globulos rojo.
TW200717389A (en) Luminance adjustment
CA111400S (en) Bottle
TW200715634A (en) Stable organic devices
SG153834A1 (en) 1-aza-bicyclo[3.3.1]nonanes
MX2010002028A (es) Metodos y composiciones para modular celulas t.
TW200722897A (en) Projection partitioning and aligning
WO2008066630A3 (en) Methods for reprogramming adult somatic cells and uses thereof
EA200800713A1 (ru) Аморфные твёрдые дисперсии
CO6241120A2 (es) (DIHIDRO)PIRROLO[2,1-á]ISOQUINOLINAS.
PL1843778T3 (pl) Kompozycje zawierające galusan epigalokatechiny i hydrolizat białkowy
PL1954009T3 (pl) Numeracja VLAN w sieciach dostępu
TW200711168A (en) Packaging designs for LEDs
GB0512609D0 (en) Lrp code 14.06.05
AU307552S (en) Crate with two open sides
AU302159S (en) Safety door stopper